Protalix Biotherapeutics Inc (PLX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Protalix Biotherapeutics Inc stock (PLX) is currently trading at $2.07. Protalix Biotherapeutics Inc PE ratio is 26.75. Protalix Biotherapeutics Inc PS ratio (Price-to-Sales) is 3.26. Analyst consensus price target for PLX is $11.00. WallStSmart rates PLX as Sell.
- PLX PE ratio analysis and historical PE chart
- PLX PS ratio (Price-to-Sales) history and trend
- PLX intrinsic value — DCF, Graham Number, EPV models
- PLX stock price prediction 2025 2026 2027 2028 2029 2030
- PLX fair value vs current price
- PLX insider transactions and insider buying
- Is PLX undervalued or overvalued?
- Protalix Biotherapeutics Inc financial analysis — revenue, earnings, cash flow
- PLX Piotroski F-Score and Altman Z-Score
- PLX analyst price target and Smart Rating
Protalix Biotherapeutics Inc
📊 No data available
Try selecting a different time range
PLX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Protalix Biotherapeutics Inc (PLX)
PLX trades 441% above its Graham fair value of $0.54, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Protalix Biotherapeutics Inc (PLX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and peg ratio. Significant fundamental concerns warrant caution or avoidance.
Protalix Biotherapeutics Inc (PLX) Key Strengths (0)
Supporting Valuation Data
Protalix Biotherapeutics Inc (PLX) Areas to Watch (10)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Revenue declining -49.90%, a shrinking business
Earnings declining -1.00%, profits shrinking
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.3x book value
Low institutional interest, mostly retail-driven
Revenue is fairly priced at 3.26x sales
Supporting Valuation Data
Protalix Biotherapeutics Inc (PLX) Detailed Analysis Report
Overall Assessment
This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 0 register as strengths (avg 0/10) while 10 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (3.26), Price/Book (3.25) suggest expensive pricing. Growth concerns include Revenue Growth at -49.90%, EPS Growth at -1.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -14.40%, Operating Margin at -51.10%, Profit Margin at -12.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -14.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -49.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PLX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PLX's Price-to-Sales ratio of 3.26x sits near its historical average of 3.61x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 13% below its historical high of 3.75x set in Mar 2026, and 0% above its historical low of 3.26x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Protalix Biotherapeutics Inc (PLX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Protalix Biotherapeutics Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 53M with 50% decline year-over-year. The company is currently unprofitable, posting a -12.5% profit margin.
Key Findings
Generating 795,000 in free cash flow and 2M in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 50% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -12.5% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Protalix Biotherapeutics Inc.
Bottom Line
Protalix Biotherapeutics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Protalix Biotherapeutics Inc(PLX)
NYSE MKT
HEALTHCARE
BIOTECHNOLOGY
USA
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.